Clinical Trial Update: CART-19 Cells for R/R B-cell Lymphoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for CART-19 cells targeting Relapsed or Refractory B-cell Lymphoma, in Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Lymphoma

Drugs mentioned

• CART-19 (CD19-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Fujian Medical University | Conditions: Relapsed or Refractory B-cell Lymphoma | Phase 2, Phase 3 | Status: UNKNOWN